MBS303 / Beijing Mabworks Biotech - LARVOL DELTA

MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase Ⅰ, Dose-Escalation Trial (ASH 2024) - P1/2 | "In FL pts of 9 mg (n=2), ORR and CMR were both 100%. Even at first cohort with target dose of 0.45 mg, response was also observed and this pt with r/r DLBCL achieved partial response.Conclusion : This study demonstrated that in pts with refractory, aggressive B-NHL, MBS303 showed favorable safety and remarkable antitumor activity in the preliminary data, even at low doses."

Clinical • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • CD20

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL (clinicaltrials.gov) - P1/2 | N=132 | Recruiting | Sponsor: Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Nov 2024 ➔ Nov 2025

Trial primary completion date • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL (clinicaltrials.gov) - P1/2 | N=132 | Recruiting | Sponsor: Beijing Mabworks Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL (clinicaltrials.gov) - P1/2 | N=132 | Not yet recruiting | Sponsor: Beijing Mabworks Biotech Co., Ltd.

New P1/2 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology